Payment overview · 2025
General Payments
$312.96
15 reported records · 8 companies
Healthcare provider profile · identity verified
Eugene Hooks Jackson, MD
Allopathic & Osteopathic Physicians|Family Medicine · FITZGERALD, GA · NPI 1538165386
Verified facts
What the public records show
CMS Open Payments records show Eugene Hooks Jackson, MD received $312.96 in general payments during 2025 across 15 reported records.
Paratek Pharmaceuticals, Inc. accounted for 27.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 11 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance, Kerendia, Ubrelvy, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 66 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 56 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported UBRELVY as an associated drug or biological on 299803 records involving 61203 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Ubrelvy by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Vraylar by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 83 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Symbicort by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Kerendia by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 70 claims for Jardiance by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Paratek Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $84.77 | 27.1% | 2 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $70.63 | 22.6% | 3 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $47.62 | 15.2% | 3 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $31.49 | 10.1% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $29.95 | 9.6% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $18.67 | 6.0% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $16.20 | 5.2% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $13.63 | 4.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $312.96 | 15 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| NUZYRA Normalized: nuzyra |
Drug | Paratek Pharmaceuticals, Inc. | $84.77 | 2 | 2025 |
Source payment records
|
|||||
| VERQUVO Normalized: verquvo |
Drug | Merck Sharp & Dohme LLC | $70.63 | 3 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $47.62 | 3 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $29.95 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $29.95 | 2 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $18.67 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $16.20 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $15.89 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $15.89 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $15.60 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $13.63 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 83 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 70 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 35 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| UBRELVY ubrelvy |
2025 | Ubrelvy | 2024 | 19 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 24 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
66 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
56 | 19 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | UBRELVY open payments reported associated product |
CMS Open Payments — General Payments 299803 supporting records · 61203 recipient NPIs · example record 1201352530 |
Ubrelvy · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
83 | 17 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
35 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
70 | 15 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 777 | 108 |
| Famotidine | Famotidine | 466 | 38 |
| Alprazolam | Alprazolam | 415 | 56 |
| Gabapentin | Gabapentin | 411 | 79 |
| Furosemide | Furosemide | 396 | 50 |
| Amlodipine Besylate | Amlodipine Besylate | 393 | 67 |
| Atorvastatin Calcium | Atorvastatin Calcium | 372 | 70 |
| Oxycodone Hcl | Oxycodone Hcl | 305 | 38 |
| Levothyroxine Sodium | Levothyroxine Sodium | 304 | 61 |
| Clopidogrel | Clopidogrel Bisulfate | 275 | 29 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 263 | 34 |
| Trazodone Hcl | Trazodone Hcl | 254 | 49 |
| Carvedilol | Carvedilol | 245 | 33 |
| Valsartan | Valsartan | 245 | 31 |
| Tramadol Hcl | Tramadol Hcl | 220 | 35 |
| Potassium Chloride | Potassium Chloride | 210 | 51 |
| Pregabalin | Pregabalin | 204 | 29 |
| Omeprazole | Omeprazole | 196 | 47 |
| Mounjaro | Tirzepatide | 192 | 28 |
| Escitalopram Oxalate | Escitalopram Oxalate | 182 | 26 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 179 | 30 |
| Clonazepam | Clonazepam | 175 | 25 |
| Duloxetine Hcl | Duloxetine Hcl | 173 | 31 |
| Lisinopril | Lisinopril | 170 | 20 |
| Pravastatin Sodium | Pravastatin Sodium | 166 | suppressed |
| Tamsulosin Hcl | Tamsulosin Hcl | 157 | 29 |
| Metformin Hcl | Metformin Hcl | 150 | 32 |
| Donepezil Hcl | Donepezil Hcl | 143 | 21 |
| Zolpidem Tartrate | Zolpidem Tartrate | 142 | 23 |
| Fluoxetine Hcl | Fluoxetine Hcl | 134 | 11 |
| Eliquis | Apixaban | 133 | 20 |
| Metoprolol Tartrate | Metoprolol Tartrate | 130 | 15 |
| Losartan Potassium | Losartan Potassium | 127 | 25 |
| Lorazepam | Lorazepam | 126 | 53 |
| Metoprolol Succinate | Metoprolol Succinate | 126 | 26 |
| Meloxicam | Meloxicam | 123 | 30 |
| Tizanidine Hcl | Tizanidine Hcl | 119 | 20 |
| Quetiapine Fumarate | Quetiapine Fumarate | 118 | 15 |
| Baclofen | Baclofen | 117 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 110 | 32 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 106 | 25 |
| Montelukast Sodium | Montelukast Sodium | 103 | 24 |
| Diazepam | Diazepam | 100 | 15 |
| Hydrochlorothiazide | Hydrochlorothiazide | 96 | 21 |
| Fluticasone Propionate | Fluticasone Propionate | 94 | 24 |
| Ropinirole Hcl | Ropinirole Hcl | 94 | 25 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 94 | 19 |
| Temazepam | Temazepam | 88 | 14 |
| Farxiga | Dapagliflozin Propanediol | 83 | 17 |
| Celecoxib | Celecoxib | 80 | 14 |
| Ozempic | Semaglutide | 80 | 14 |
| Spironolactone | Spironolactone | 80 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 78 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 78 | suppressed |
| Pantoprazole Sodium | Pantoprazole Sodium | 76 | 21 |
| Xarelto | Rivaroxaban | 76 | 12 |
| Sucralfate | Sucralfate | 75 | 18 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 74 | 20 |
| Levofloxacin | Levofloxacin | 73 | 52 |
| Sertraline Hcl | Sertraline Hcl | 71 | 21 |
| Jardiance | Empagliflozin | 70 | 15 |
| Atenolol | Atenolol | 68 | suppressed |
| Prednisone | Prednisone | 68 | 31 |
| Buspirone Hcl | Buspirone Hcl | 66 | 16 |
| Creon | Lipase/Protease/Amylase | 66 | suppressed |
| Ezetimibe | Ezetimibe | 66 | suppressed |
| Carisoprodol | Carisoprodol | 64 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 63 | suppressed |
| Levetiracetam | Levetiracetam | 63 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 61 | 42 |
| Simvastatin | Simvastatin | 61 | 14 |
| Januvia | Sitagliptin Phosphate | 60 | 11 |
| Ondansetron Hcl | Ondansetron Hcl | 60 | 23 |
| Linzess | Linaclotide | 56 | 19 |
| Tradjenta | Linagliptin | 56 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 55 | suppressed |
| Glimepiride | Glimepiride | 54 | 12 |
| Mirtazapine | Mirtazapine | 54 | 15 |
| Dicyclomine Hcl | Dicyclomine Hcl | 53 | 14 |
| Diclofenac Sodium | Diclofenac Sodium | 51 | 17 |
| Azithromycin | Azithromycin | 49 | 43 |
| Estradiol | Estradiol | 49 | 11 |
| Ibuprofen | Ibuprofen | 49 | suppressed |
| Myrbetriq | Mirabegron | 49 | 13 |
| Colchicine | Colchicine | 48 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 48 | suppressed |
| Fluconazole | Fluconazole | 47 | 30 |
| Metoclopramide Hcl | Metoclopramide Hcl | 47 | 14 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 46 | 12 |
| Topiramate | Topiramate | 44 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 43 | suppressed |
| Primidone | Primidone | 43 | suppressed |
| Glipizide | Glipizide | 41 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 40 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 39 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 38 | 25 |
| Irbesartan | Irbesartan | 38 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 37 | 31 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 36 | suppressed |
| Memantine Hcl | Memantine Hcl | 36 | suppressed |
| Allopurinol | Allopurinol | 35 | suppressed |
| Bupropion Xl | Bupropion Hcl | 35 | suppressed |
| Kerendia | Finerenone | 35 | suppressed |
| Lansoprazole | Lansoprazole | 35 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 35 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 33 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 33 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 33 | suppressed |
| Lactulose | Lactulose | 32 | suppressed |
| Ranolazine Er | Ranolazine | 32 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 31 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 31 | 12 |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 30 | suppressed |
| Ondansetron Odt | Ondansetron | 29 | suppressed |
| Rabeprazole Sodium | Rabeprazole Sodium | 29 | suppressed |
| Entresto | Sacubitril/Valsartan | 28 | suppressed |
| Glipizide Er | Glipizide | 28 | suppressed |
| Ramipril | Ramipril | 28 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 26 | suppressed |
| Lamotrigine | Lamotrigine | 26 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 25 | suppressed |
| Levemir | Insulin Detemir | 25 | suppressed |
| Methocarbamol | Methocarbamol | 25 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 25 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 24 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 24 | suppressed |
| Vraylar | Cariprazine Hcl | 24 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 23 | suppressed |
| Vilazodone Hcl | Vilazodone Hcl | 23 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 22 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 22 | suppressed |
| Methotrexate | Methotrexate Sodium | 22 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 22 | suppressed |
| Aripiprazole | Aripiprazole | 21 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 21 | suppressed |
| Latanoprost | Latanoprost | 21 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 21 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 21 | 14 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 21 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 20 | suppressed |
| Humalog | Insulin Lispro | 20 | suppressed |
| Metolazone | Metolazone | 20 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 19 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 19 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 19 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 19 | 16 |
| Ubrelvy | Ubrogepant | 19 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 19 | suppressed |
| Fentanyl | Fentanyl | 18 | suppressed |
| Nitroglycerin Patch | Nitroglycerin | 18 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 18 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 17 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 17 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 17 | suppressed |
| Methylprednisolone | Methylprednisolone | 17 | suppressed |
| Mupirocin | Mupirocin | 17 | 12 |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 17 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 16 | suppressed |
| Hydromorphone Hcl | Hydromorphone Hcl | 16 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 16 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 16 | suppressed |
| Aimovig Autoinjector | Erenumab-Aooe | 15 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 15 | suppressed |
| Levemir Flexpen | Insulin Detemir | 15 | suppressed |
| Olanzapine | Olanzapine | 15 | suppressed |
| Pyridostigmine Bromide | Pyridostigmine Bromide | 15 | suppressed |
| Trueplus Insulin Syringe | Syringe-Needle,insulin,0.5 Ml | 15 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 14 | suppressed |
| Invokamet | Canagliflozin/Metformin Hcl | 14 | suppressed |
| Itraconazole | Itraconazole | 14 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 14 | suppressed |
| Rayaldee | Calcifediol | 14 | suppressed |
| Risperidone | Risperidone | 14 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 14 | suppressed |
| Silodosin | Silodosin | 14 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 14 | suppressed |
| Synthroid | Levothyroxine Sodium | 14 | suppressed |
| Trulicity | Dulaglutide | 14 | suppressed |
| Unifine Safecontrol Pen Needle | Pen Needle,dual Safety,diabetc | 14 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 13 | suppressed |
| Fenofibric Acid | Fenofibric Acid (Choline) | 13 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 13 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 13 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 13 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 13 | suppressed |
| Repatha Sureclick | Evolocumab | 13 | suppressed |
| Risedronate Sodium | Risedronate Sodium | 13 | suppressed |
| Sotalol | Sotalol Hcl | 13 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 13 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 12 | 12 |
| Carbamazepine | Carbamazepine | 12 | suppressed |
| Hysingla Er | Hydrocodone Bitartrate | 12 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 12 | suppressed |
| Mesalamine | Mesalamine | 12 | suppressed |
| Nystatin | Nystatin | 12 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 12 | suppressed |
| Premarin | Estrogens, Conjugated | 12 | suppressed |
| Propafenone Hcl | Propafenone Hcl | 12 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 12 | suppressed |
| Xtampza Er | Oxycodone Myristate | 12 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 11 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 11 | suppressed |
| Epinephrine | Epinephrine | 11 | suppressed |
| Ketoconazole | Ketoconazole | 11 | suppressed |
| Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 11 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 11 | suppressed |
| Oxycontin | Oxycodone Hcl | 11 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 11 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $312.96 · 15 records | Paratek Pharmaceuticals, Inc. | CAPLYTA, FARXIGA, JARDIANCE, Kerendia, NUZYRA, OTEZLA, QULIPTA, REPATHA, UBRELVY, VERQUVO, VRAYLAR | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error